Prostatectomies Using Einstein Vision® 3D
Launched by AESCULAP AG · Dec 9, 2016
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing planned radical prostatectomy prostatectomy because of histologically proven prostate cancer using EinsteinVision®
- • Written informed consent
- • Age ≥ 18 years
- Exclusion Criteria:
- • Previous TURP (= transurethral resection of the prostate)
- • Previous operations on the sigmoid colon or rectum (e.g. because of carcinoma, perforation, diverticulum)
- • BMI \> 35 kg/m²
- • Participation in another clinical study
- • Representation by a legal guardian or under involuntary commitment
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Offenbach, , Germany
Ostfildern, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials